Syndyam 400 mg Injection
  1. Home
  2. Pharma Products
  3. Cipla Ltd
  4. Syndyam 400 mg Injection

Syndyam 400 mg Injection

Syndyam 400 mg Injection contains bevacizumab 400 mg, a monoclonal antibody used for several types of cancer. It is administered by intravenous infusion under the supervision of a healthcare professional. Bevacizumab blocks VEGF, helping reduce the formation of blood vessels that supply tumors.

BUY NOW

Category

Syndyam 400 mg Injection is used in conditions including metastatic colorectal cancer, non-small cell lung cancer, kidney cancer, ovarian cancer, cervical cancer, and certain brain tumors. Bevacizumab belongs to the VEGF inhibitor class and interferes with tumor blood-vessel formation. The dose and treatment schedule are determined by the treating oncologist according to the cancer type and treatment protocol. Medical monitoring is required during treatment because bevacizumab can cause clinically significant adverse effects.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 400 mg
Dosage Form Injection / Concentrate for Infusion
Route of Administration Intravenous Infusion
Pack Size 16 mL in 1 Vial
Manufacturer/Marketer Cipla Ltd.

Product Also Known As

Syndyam 400 mg Injection, Syndyma 400 mg Injection, Syndyma 400 Injection, Syndyma Bevacizumab Injection, Bevacizumab 400 mg Injection, Bevacizumab 400 mg/16 mL Injection